UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News:
Orexo AB publ (STO:ORX)
STRONG REVENUE GROWTH AND CASH FLOW. ALL CLINICAL STUDIES FOR KEY PROJECT OX219 COMPLETED AHEAD OF PLAN.
Unless otherwise stated in this report, all data refers to the Group. Figures in parentheses relate to the corresponding period in 2011.
